<DOC>
	<DOCNO>NCT00703612</DOCNO>
	<brief_summary>The purpose study determine whether intravenous administration autologous adipose-derived stem cell benefit management type 2 diabetic .</brief_summary>
	<brief_title>Safety Efficacy Autologous Adipose-Derived Stem Cell Transplantation Type 2 Diabetics</brief_title>
	<detailed_description>Diabetes Mellitus large epidemic proportion worldwide . It proliferate fast rate new novel drug therapeutic approach require . The purpose Phase 1/Phase 2 study determine whether intavenous administration activate adipose-derived stromal vascular fraction single procedure safe benefit disease pathology patient Type 2 Diabetes Mellitus ( insulin resistance ) . Patients observe 12 month follow procedure , 2 week , 1 month tri monthly diagnostics life style questionaires .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Confirmed diagnosis Type II diabetes least 2 year Type 2 diabetic oral hypoglycemic agent and/or insulin Fasting blood sugar &gt; 200mg % least two occasion Willing keep weekly diary undergo observation 12 month Presence previous and/or acute diabetic complication myocardial infarction , CVA nephropathy</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Adipose-derived stem cell</keyword>
	<keyword>Adipose stromal vascular fraction</keyword>
	<keyword>Autologous</keyword>
	<keyword>Hyperglycemia</keyword>
</DOC>